This guide will help you understand how NSCLC is treated, potential side effects, and how to navigate life beyond cancer.

Johnson & Johnson JNJ announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use ...

Sleep disorders occur frequently and are underrecognized in patients with non-small cell lung cancer, according to a rapid ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

Severing ties with Canada, becoming a non-resident, tax obligations, and tax on Canadian-source income Benefits, credits and taxes for newcomers to Canada (immigrants and returning residents) Tax ...

Use these LGBTQ+ grants and funding resources to launch and grow your business. Many, or all, of the products featured on this page are from our advertising partners who compensate us when you ...

AstraZeneca is a leader in cancer treatments with FDA-approved drugs. Read why AZN stock is still a 'Buy' and why the company’s future looks bright.

and Imfinzi (durvalumab) in NHS patients across England and Wales. Tagrisso has been recommended for use as an adjuvant treatment following complete resection in adults with stage 1B to 3A non-small ...

A representative from MusiCares stated, “MusiCares is a resource to music professionals impacted by the fires in the Los Angeles area. MusiCares provides short-term disaster relief, including $ ...

Most of the existing resource allocation schemes in NOMA-MEC networks are based on the centralized optimization framework, which may increase the communicational and computational burden on the ...

The eligibility criteria for this study include NSCLC patients receiving standard-of-care chemoradiation followed by consolidation immunotherapy with AstraZeneca’s Imfinzi (durvalumab).

Various PD-1 and PD-L1 checkpoint inhibitors have been approved by U.S. regulators including blockbuster drugs Keytruda, Imfinzi, and Opdivo to treat ... patients with PD-L1-positive advanced ...